SCHEMBL873793

SCHEMBL873793

O=C1CC(O)(S(=O)(=O)O)C(=O)N1.[NaH]

nearest known ligand 0.33

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21995 0.98 TSHR (0.34) TSHRNPSR1
SCHEMBL10760706 0.71 TSHR (0.32) TSHRNPSR1
SCHEMBL3255645 0.66
Sulfuric Acid SCHEMBL27857454 0.64 TSHR (0.41) TSHRNPSR1
SCHEMBL3263772 0.63 TSHR (0.32) TSHRNPSR1
SCHEMBL4637001 0.62
Ethylene SCHEMBL4351883 0.62 TSHR (0.38) TSHRNPSR1
Succinimide SCHEMBL8613393 0.61 CRBN (0.65)
Bicarbonate SCHEMBL9560500 0.61 TSHR (0.37) TSHRNPSR1
SCHEMBL13805603 0.59 TSHR (0.44) TSHRNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3538891-A2 COMPOSITIONS AND METHODS FOR THE SIMULTANEOUS GENOMIC, TRANSCRIPTOMIC AND PROTEOMIC ANALYSIS OF SINGLE CELLS Isoplexis Corporation (US) 2019-09-18 EP claimed
WO-2018089910-A2 COMPOSITIONS AND METHODS FOR THE SIMULTANEOUS GENOMIC, TRANSCRIPTOMIC AND PROTEOMIC ANALYSIS OF SINGLE CELLS IsoPlexis Corporation (US) 2018-05-17 WO claimed
EP-1420681-A4 PEPTIDE-BASED MULTIMERIC TARGETED CONTRAST AGENTS EPIX PHARM INC (US) 2009-08-05 EP claimed
WO-2009080308-A1 MEANS ANDS METHODS OF PROCESSING BIOLOGICAL SAMPLES MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2009-07-02 WO claimed
EP-1420681-A2 PEPTIDE-BASED MULTIMERIC TARGETED CONTRAST AGENTS Epix Medical, Inc. (US) 2004-05-26 EP claimed
WO-2003011115-A2 PEPTIDE-BASED MULTIMERIC TARGETED CONTRAST AGENTS EPIX MEDICAL, INC. (US) 2003-02-13 WO claimed
EP-4377363-A1 FUNCTIONALISATION OF CARBOXYMETHYLCELLULOSE The University of Manchester (GB) 2024-06-05 EP disclosed
EP-4370163-A1 BRAIN PERMEABLE MULTIFUNCTIONAL SYSTEM AND USES THEREOF Nanocarry Therapeutics Ltd. (IL) 2024-05-22 EP disclosed
EP-4337174-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF VIRAL INFECTION Technion Research & Development Foundation Limited (IL) 2024-03-20 EP disclosed
WO-2024028465-A1 HYBRID PEPTIDE DENDRIMER SYSTEMS AND EXTRAHEPATIC DELIVERY NUNTIUS THERAPEUTICS LIMITED (GB) 2024-02-08 WO disclosed
WO-2024020237-A1 WEARABLE MICROFLUIDIC BIOAFFINITY SENSOR FOR AUTOMATIC MOLECULAR ANALYSIS CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2024-01-25 WO disclosed
WO-2023223307-A1 MULTIFUNCTIONAL DELIVERY SYSTEM AND USES THEREOF Nanocarry Therapeutics Ltd. (IL) 2023-11-23 WO disclosed
EP-4267208-A1 CONDUCTIVE SCAFFOLDS FORMED BY ABSORBABLE COMPOSITE BIOMATERIALS AND USE THEREOF Conductivebio Incorporated (US) 2023-11-01 EP disclosed
EP-1390370-A1 METHODS FOR PREPARATION OF CYTOTOXIC CONJUGATES OF MAYTANSINOIDS AND CELL BINDING AGENTS Immunogen, Inc. (US) 2004-02-25 EP disclosed
WO-2002098883-A1 METHODS FOR PREPARATION OF CYTOTOXIC CONJUGATES OF MAYTANSINOIDS AND CELL BINDING AGENTS IMMUNOGEN, INC. (US) 2002-12-12 WO disclosed
EP-0730737-A4 ENZYME AMPLIFIED COMPETITIVE AND SANDWICH CHELATION ASSAYS FOR METAL IONS UNIV CALIFORNIA (US) 1999-02-03 EP disclosed
EP-0730737-A1 ENZYME AMPLIFIED COMPETITIVE AND SANDWICH CHELATION ASSAYS FOR METAL IONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1996-09-11 EP disclosed
WO-1995014926-A1 ENZYME AMPLIFIED COMPETITIVE AND SANDWICH CHELATION ASSAYS FOR METAL IONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1995-06-01 WO disclosed
EP-0577659-A1 CROSS-LINKING AGENT. HOLMES MICHAEL JOHN (GB) 1994-01-12 EP disclosed
WO-1992017436-A1 CROSS-LINKING AGENT HOLMES, MICHAEL, JOHN (GB) 1992-10-15 WO disclosed